Compare Ascendis Pharma A/S (ASND) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs TotalEnergies SE — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while TotalEnergies SE trades at $80.13 (market cap $173.13B). The key difference: TotalEnergies SE is far larger — about 9.8× Ascendis Pharma A/S's market cap, and TotalEnergies SE pays a 5.37% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TTE | |
|---|---|---|
Market Cap | $17.74B | $173.13B |
Sector | Health | Energy |
52-Week High | $277.18 | $93.60 |
52-Week Low | $163.32 | $57.39 |
Enterprise Value | $18.11B | $207.27B |
Dividend Yield | — | 5.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TTE trades at $78.5, up 0.35% today, with a neutral technical signal and mixed earnings history including a Q1 2026 beat. Valuation ratios appear attractive with a P/E of 11.65 and EV/EBITDA of 4.81. Recent news highlights strategic divestments and new LNG shipments, while cash flow trends show stabilization after recent declines.
Outlook is cautiously positive given strong analyst buy ratings (57.58%) and shareholder returns via dividends, but risks include revenue declines, geopolitical exposure, and regulatory pressures. The stock offers value characteristics with moderate growth prospects amid energy sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
